tiprankstipranks
Alnylam Pharmaceuticals (GB:0HD2)
LSE:0HD2
UK Market
0HD2
Alnylam Pharma
RESEARCH TOOLSreports

Alnylam Pharma (0HD2) Income Statement

4 Followers

Alnylam Pharma Income Statement

Last quarter (Q4 2025), Alnylam Pharma's total revenue was $1.10B, an increase of 84.95% from the same quarter last year. In Q4, Alnylam Pharma's net income was $186.42M. See Alnylam Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 3.71B$ 2.25B$ 1.83B$ 1.04B$ 844.29M
Gross Profit
$ 3.04B$ 1.92B$ 1.52B$ 868.60M$ 704.14M
Operating Expenses
$ 2.54B$ 2.10B$ 1.80B$ 1.65B$ 1.41B
Depreciation and Amortization
$ 55.66M$ 56.67M$ 54.05M$ 44.47M$ 47.57M
EBITDA
$ 557.24M$ -178.85M$ -258.24M$ -926.56M$ -661.56M
Operating Income
$ 501.58M$ -176.88M$ -282.18M$ -785.07M$ -708.65M
Other Income/Expenses
$ -178.43M$ -200.49M$ -151.34M$ -341.92M$ -143.49M
Pretax Income
$ 323.15M$ -377.38M$ -433.52M$ -1.13B$ -852.14M
Net Income
$ 313.75M$ -278.16M$ -440.24M$ -1.13B$ -852.82M
Per Share Metrics
Basic EPS
$ 2.39$ -2.18$ -3.52$ -9.30$ -7.20
Diluted EPS
$ 2.33$ -2.18$ -3.52$ -9.30$ -7.20
Weighted Average Shares Outstanding
 131.00M 127.65M 124.91M 121.69M 118.45M
Weighted Average Shares Outstanding (Diluted)
 134.68M 127.65M 124.91M 121.69M 118.45M
Currency in USD

Alnylam Pharma Earnings and Revenue History